Cargando…

Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of lung cancer. However, their clinical benefit is limited to a minority of patients. To unravel immune-related factors that are predictive of sensitivity or resistance to immunotherapy, we performed a gene expression analysis by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baglivo, Sara, Bianconi, Fortunato, Metro, Giulio, Gili, Alessio, Tofanetti, Francesca Romana, Bellezza, Guido, Ricciuti, Biagio, Mandarano, Martina, Teti, Valeria, Siggillino, Annamaria, Reda, Maria Sole, Chiari, Rita, Pistola, Lorenza, Sidoni, Angelo, Minotti, Vincenzo, Roila, Fausto, Ludovini, Vienna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303258/ https://www.ncbi.nlm.nih.gov/pubmed/34209514 http://dx.doi.org/10.3390/genes12070992

Ejemplares similares

High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
por: Ludovini, Vienna, et al.
Publicado: (2021)

Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR
por: Siggillino, Annamaria, et al.
Publicado: (2020)

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
por: Metro, Giulio, et al.
Publicado: (2021)

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature
por: Baglivo, Sara, et al.
Publicado: (2020)

Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature
por: Baglivo, Sara, et al.
Publicado: (2022)

Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study
por: Foglietta, Jennifer, et al.
Publicado: (2020)

Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study
por: Ludovini, Vienna, et al.
Publicado: (2017)

Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer
por: Mandarano, Martina, et al.
Publicado: (2021)

Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review
por: Metro, Giulio, et al.
Publicado: (2020)

Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool
por: Mandarano, Martina, et al.
Publicado: (2020)

Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis
por: Ludovini, Vienna, et al.
Publicado: (2016)

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
por: Ricciuti, Biagio, et al.
Publicado: (2017)

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report
por: Metro, Giulio, et al.
Publicado: (2015)

Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy
por: Ludovini, Vienna, et al.
Publicado: (2017)

INSL4 as prognostic marker for proliferation and invasiveness in Non-Small-Cell Lung Cancer
por: Scopetti, Damiano, et al.
Publicado: (2021)

Dyskerin and TERC expression may condition survival in lung cancer patients
por: Penzo, Marianna, et al.
Publicado: (2015)

miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance
por: Ricciuti, Biagio, et al.
Publicado: (2015)

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
por: Ricciuti, Biagio, et al.
Publicado: (2018)

Polyangiitis overlap syndrome: a rare clinical entity
por: Bruno, Lorenza, et al.
Publicado: (2023)

Non-coding RNAs in lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2014)

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors
por: Baldelli, Elisa, et al.
Publicado: (2015)

A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: A case report
por: Colombo, Mara, et al.
Publicado: (2023)

Corrigendum: A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: a case report
por: Colombo, Mara, et al.
Publicado: (2023)

Erratum to: ‘Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology’
por: Bianconi, Fortunato, et al.
Publicado: (2016)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

Genome-wide expression of the residual lung reacting to experimental Pneumonectomy
por: Napolioni, Valerio, et al.
Publicado: (2021)

Urinary Diagnostic Cytology Beyond the Research of Neoplastic Cells: Usefulness of Erythrocyte Morphology Evaluation to Recognize Microhematuria Source
por: Del Sordo, Rachele, et al.
Publicado: (2023)

Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR
por: Caselli, Emanuele, et al.
Publicado: (2021)

Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models
por: Baldelli, Elisa, et al.
Publicado: (2021)

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks
por: De Giglio, Andrea, et al.
Publicado: (2023)

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience
por: Molica, Carmen, et al.
Publicado: (2023)

Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties
por: Prodosmo, Andrea, et al.
Publicado: (2008)

Current Challenges for IDO2 as Target in Cancer Immunotherapy
por: Mondanelli, Giada, et al.
Publicado: (2021)

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
por: Marinelli, Daniele, et al.
Publicado: (2022)

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient
por: Ricciuti, Biagio, et al.
Publicado: (2016)

Advanced non-small-cell lung cancer: how to manage non-oncogene disease
por: De Giglio, Andrea, et al.
Publicado: (2022)

Non-small-cell lung cancer: how to manage RET-positive disease
por: Andrini, Elisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6ac29qhaf6na5m4i40doqddfed